



1st February, 2017

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 532526
---	--

Sub. : Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015: the Company has received EIR from US FDA for its Bavla Facility

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform that the Company's Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on 9th July, 2016. In this regard, we are pleased to share that the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility today.


Thus, the Company's facilities in Bavla, Naroda and Switzerland continue to be approved by the US FDA.

Kindly take this on your record & oblige.

Thanking you.

Yours faithfully,
For, Dishman Pharmaceuticals and Chemicals Limited

S.D. Dave
Shrima Dave
Company Secretary



Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329